# Monita Dukhia

> Monita Dukhia is a San Francisco-based clinical-trial executive and compliance adviser whose career spans laboratory quality control, regulatory compliance, global GxP quality assurance, and CRO leadership. Educated in chemistry and biochemistry at McMaster University, she has led ClinPro Trials, runs GXP consulting work, and now advances an operating idea she calls AXIS-MD: that large organizations usually reveal their weaknesses at the interfaces between teams rather than inside any single function.

- **Role:** Executive at GXP AXIS-MD Consulting and CEO of ClinPro Trials
- **Organizations:** GXP AXIS-MD Consulting, ClinPro Trials, GXP Consulting, OXiGENE, Novartis Vaccines and Diagnostics, Apotex, Chief, Lion of Judah Ministries
- **Education:** Undergraduate degree in chemistry and biochemistry, McMaster University
- **Known for:** Built a career of approximately three decades across pharmaceutical quality control, regulatory compliance, global GxP quality assurance and clinical-trial operations., Led ClinPro Trials as CEO and publicly positioned compliance and inspection readiness across the full development lifecycle., Held senior quality and compliance roles at OXiGENE and Novartis Vaccines and Diagnostics after beginning in quality control at Apotex.

## Career timeline

- **1996** — Began her professional career, later summarized as starting in laboratory quality and compliance work.
- **Date not public** — Worked as a QCI supervisor at Apotex.
- **Date not public** — Served as manager of regulatory compliance at Novartis Vaccines and Diagnostics.
- **Date not public** — Served as global director of GxP quality assurance at OXiGENE.
- **2010** — GXP Consulting was filed in California; public records identify Dukhia as CEO, CFO, secretary and director.
- **2011** — Lion of Judah Ministries received federal tax-exempt status, with Dukhia named in care of the organization.
- **2020** — As CEO of ClinPro Trials, described a compliance-led, full-service CRO model spanning drug development from concept to commercialization.
- **2022** — Included at No. 40 in Women We Admire's Top 50 Women CEOs list.
- **2025** — Highlighted by an industry recruiter as a woman leading in the CRO sector with more than 20 years of clinical-trial and GxP compliance experience.
- **2026** — Public filings show new applications around Enterprise Execution Intelligence, Interface Intelligence and related AXIS-MD concepts, alongside newly formed EEI entities.

## Achievements

- Built a career of approximately three decades across pharmaceutical quality control, regulatory compliance, global GxP quality assurance and clinical-trial operations.
- Led ClinPro Trials as CEO and publicly positioned compliance and inspection readiness across the full development lifecycle.
- Held senior quality and compliance roles at OXiGENE and Novartis Vaccines and Diagnostics after beginning in quality control at Apotex.
- Included in Women We Admire's 2022 Top 50 Women CEOs list.
- Developed and publicly articulated the AXIS-MD framework around alignment, interfaces, execution and source.
- Published multiple books listed by Goodreads, including Out of the Miry Clay and The Return of the King.

## Latest updates

- **2026-09** — Continues publishing about AXIS-MD and enterprise execution coherence, with recent posts applying the framework to inspections, scaling biotechnology companies and cross-functional alignment.
- **2026-07** — Filed an intent-to-use application for the phrase AI AMPLIFIES. EEI ORCHESTRATES for business consulting services.
- **2026-06** — Filed an intent-to-use application for EEI UNDERSTANDING ENGINE for business training services.
- **2026-05** — Filed applications for Enterprise Execution Intelligence and Interface Intelligence and was named registered agent for newly formed EEI entities in California.

## Links

- Website: https://clinprotrials.com
- LinkedIn: https://www.linkedin.com/in/monita-dukhia-2125615
- Twitter/X: https://twitter.com/RevMonita

---

Profile page: https://yespress.io/monita-dukhia
Published by YesPress — https://yespress.io
Last updated: 2026-09-27